enGene Therapeutics Inc. ENGN
NASDAQ
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -32.50M | -30.23M | -29.75M | -37.88M | -28.99M |
| Total Depreciation and Amortization | 178.00K | 180.00K | 189.00K | 171.00K | 130.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.94M | 4.15M | 3.20M | 2.62M | 2.16M |
| Change in Net Operating Assets | 5.44M | -4.60M | -2.54M | 10.13M | 1.07M |
| Cash from Operations | -18.95M | -30.50M | -28.90M | -24.96M | -25.63M |
| Capital Expenditure | 0.00 | -98.00K | -153.00K | -437.00K | -704.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 30.12M | 23.74M | -126.14M | 40.94M | 2.08M |
| Cash from Investing | 30.12M | 23.64M | -126.30M | 40.50M | 1.38M |
| Total Debt Issued | 0.00 | 0.00 | 25.00M | -- | -- |
| Total Debt Repaid | 0.00 | 0.00 | -23.05M | 0.00 | -699.00K |
| Issuance of Common Stock | 23.00K | 4.00K | 149.78M | 1.99M | 32.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 70.00K | -10.06M | -- | -- |
| Cash from Financing | 23.00K | 74.00K | 141.66M | 1.99M | -667.00K |
| Foreign Exchange rate Adjustments | 0.00 | 0.00 | 1.00K | 0.00 | 0.00 |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 11.20M | -6.79M | -13.54M | 17.53M | -24.92M |